‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal
07-09-2023
LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission
01-02-2021
Pajor Pawel / Shutterstock.com
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.
Before news broke last week of the new Horizon funding deal for the UK, IP law firm Mathys & Squire reported that the UK’s 50 biggest universities filed 433 new patent applications in the period 2021-2022.
This number fell from 474 in 2020-2021—the year of Brexit and the withdrawal of funding from Horizon Europe—representing a decline of 9%.
Despite the dip, these figures are proof that UK universities continued to be among the world’s most innovative, despite the removal, albeit temporarily, of this valuable source of EU funding.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
UK, university, Horizon Pharma, patents, Mathys & Squire, Brexit, innovation, COVID-19, vaccine, MIT, Harvard, biotechnology, pharmaceuticals, technology
